The FDA approves Vaxelis, a pediatric hexavalent combination vaccine developed as a JV between Sanofi (SNY +0.2%) and Merck (MRK +2%).
The vaccine is indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b in patients aged 6 weeks to 4 years.
The companies are working to maximize production to meet U.S. demand will a commercial launch happening no sooner than 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.